Origin, pattern of bone metastasis and need for surgery in patients with Metastatic bone disease treated at tertiary hospital in Northern Tanzania. A hospital based cross sectional study

- 4
- 5 Mathias Ncheye^{1,2}, Elifuraha Maya^{1,2}, Furaha Serventi^{1,3}, Faiton
- 6 Mandari^{1,2}, Rogers Temu^{1,2}, Peter Magembe¹, Honest Massawe^{1,2}
- 7
- ⁸ ¹Kilimanjaro Christian Medical University College, Kilimanjaro,
- 9 Tanzania
- ¹⁰ ² Department of Orthopedics and Trauma, Kilimanjaro Christian
- 11 Medical Centre, Kilimanjaro, Tanzania
- ¹² ³ Cancer Care Centre, Kilimanjaro Christian Medical Centre,
- 13 Kilimanjaro, Tanzania
- 14
- 15 *Corresponding Author
- 16 E-mail: <u>suitmats@gmail.com</u>
- 17
- 18

19 Abstract

Bones are the third most common sites for cancer metastasis after lung and liver. Bone metastasis cause skeletal complications (SRE's) that affect the quality of life of patients with bone metastasis. Management of these patients depend on the primary tumor and pattern of bone metastasis.

The aim of this study was to describe the origin, distribution pattern of bone metastases,
common SRE's and proportion of patients with bone metastasis that need surgery.

A cross sectional study was conducted among cancer patients with Metastatic bone disease attending KCMC Hospital from November 2022 to April 2023. Data was collected from patient's files, histopathology and radiology reports by a structured extraction sheet. VAS, SINS and Mirel's scores was used to document pain severity, spinal instability and fracture risk respectively. The ASIA impairment scale was used for documenting neurological deficits in patients with spine metastasis. Data was entered and analyzed in SPSS version 25.0

32 A total of 72 participants were enrolled. Their mean age was 69 ± 11 years and (75%) were 33 male. Prostate cancer (65.3%) was the leading cause of metastatic bone disease followed by breast 34 cancer (18.1%). Most of patients with MBD have multiple lesions (91.7%) involving multiple sites 35 but the spine (93.1%) was the mostly affected site. Osteoblastic lesions were the predominant 36 radiological type by 59.7% followed by osteolytic lesions which accounted for 23.6% of the study 37 participants. 30.6% had pathological fractures and half of these occurred in patients with 38 osteolytics lesions. 36.1% of the study participants had an indication for surgical treatment of the 39 bone metastasis.

Most of MBD originate from Prostate and Breast cancer giving multiple lesions involving multiple sites but the spine remains to be the most affected site. Even though about a third of the patients had SRE's that needed surgical intervention but few are expected to be operated considering the prognosis. This calls for more emphasis on prevention of SRE's and use of appropriate less invasive therapies to prevent progression of the disease.

46 Introduction

In the US, it is estimated that about 5% of all cancer patients have bone metastasis, the
common primary cancers been breast, prostate and lung cancer accounting for almost 70% of all
bone metastasis. (1,2)

In our setting, Bone metastasis is one of the most common musculoskeletal tumors just second to osteosarcoma.(3) Studies that have investigated on common primary malignancies like breast and prostate cancer have shown that most patients present late and bone metastasis is present in 24-58% of the patients.(4–7)

Most patients present to the orthopedic surgeon with pain, pathological fractures or symptoms due to spinal cord compression. These are called skeletal related events (SRE's). These cause significant morbidity and affect the quality of life of patients with cancer. The onset of SRE's has been shown to vary depending on the primary tumor, metastatic site and the radiological pattern.(8,9)

59 Surgical management of bone metastasis has been shown to help improve quality of life, 60 in patients with metastatic bone disease. It can be done to fix a pathological fracture, to decompress 61 spinal cord compression due to spine metastasis or even to prevent an impending pathological 62 fracture in long bones. Surgery is also done for patients with intractable pain that does not respond 63 to opioids or radiotherapy. (10–12)

Due to the advancement of cancer treatment now patients with cancer live longer and so the incidence and prevalence of bone metastasis is also Increasing. The data on on the distribution pattern of bone metastasis and the proportion of patients with metastatic bone disease who need surgery in our setting is limited.

We aim to describe the origin, distribution pattern of bone metastases and proportion ofpatients with bone metastasis that need surgery.

71 Materials and Methods

72 Study Area and setting

We conducted a Hospital based cross section study among cancer patients with metastatic bone
disease attending at Kilimanjaro Christian Medical center (KCMC), a tertiary and consultant
hospital in Northern Tanzania with bed capacity of 721. It serves approximately 11 million people
from this part of the country as per 2022 census.

Study participants were recruited at the clinic of cancer care center after identifying them in the cancer registry. Only those with confirmed bone metastasis and who were receiving care at the hospital from 1st November, 2022 to 30th April, 2023 were included. Data was collected during this 6 Months period but data processing and analysis was done from May 2023 to July 2023. The author had access to identification informations of the participants during and after data collection.

82

83 Eligibility criteria

84 Inclusion criteria

All cancer patients with metastatic bone disease treated at KCMC from November 2022 toApril 2023.

87 Exclusion criteria

Patients who have already received surgical treatment of bone metastasis, no histologicalresults of primary tumor and those with missing information were excluded.

90

91 Variables

92 Outcomes were skeletal related events (SRE's) and Need for surgery. Predictors were Age, Sex,

93 Type of primary cancer, Location of metastatic lesion, number of lesions and radiological type of

94 metastatic lesion.

95 Data sources and measurements

Demographic data was obtained by a structured questionnaire after obtaining a signed informed consent (S1 File) and secondary data was collected from patient's files, histopathology and radiology reports by a structured extraction sheet. Skeletal-survery CT scan and MRI images were reviewed by the principle investigator to document the pattern and presence of spinal cord compression respectively.

VAS, SINS and Mirel's scores was used to document pain severity, spinal instability and
 long bone fracture risk respectively. These scores have been shown to be valid and reliable than
 clinical judgment.(13–15) The ASIA impairment scale (S2 File) was used for documenting
 neurological deficits in patients with spine metastasis.

105 Study size

106 433 cancer patients were registered during the study period. A total of 130 patients had 107 metastatic cancer at different sites, these were filtered and we were able to identify a total of 79 108 patients with metastatic bone disease. 7 were excluded due to missing information. 72 study 109 participants were left for the final analysis.

110

111 Data Processing and Analysis plan

Data was entered and analysed by SPSS version 23.0 statistical package. Categorical variables
were summarized by frequencies and percentages in tables, bars and charts. Numerical variables
were summarized by measures of central tendacyi.e mean (S.D) and median (Range)

115

Chi square/fishers exact test was performed to compare differences in proportions of SRE's
between different groups and P value less than 0.05 was considered statistically significant.

118

120 Ethics statement

- 121 Approval to conduct the research was obtained from the Kilimanjaro Christian Medical
- 122 University College Research, Ethics and Review Committee (CRERC) with clearance number
- 123 PG94/2022. Written informed consent was obtained from participants before participating in the
- 124 study.

125 **Results**

126 Social demographic information and other patients' Characteristics N=72

Most of patients with metastatic bone disease were elderly with a mean age was 69±11 years and the majority (47.1%) were aged between 60 to 74 years. 75% of the study participants were male and 76.4% of the study participants had some form of health insurance.

- 130 More than half of the study participants were on chemotherapy (59.7%) and/or hormonal
- therapy (58.3%). 43.1% of the participants had received surgical treatment for resection of the
- 132 primary tumor and 38.9% were on bisphosphonates. Radiotherapy was the least among the
- treatments with only 11.1% of the participants who had received it during the course of their
- treatment. This information is shown in tables 1 and 2 below
- 135
- 136

137 Table 1. Social demographic characteristics N=72

Variable	N (%)	
Age (Years)		
<=59	13(18.1)	
60-74	34(47.1)	
75+	25(34.7)	
Mean (S.D) = 69 (11) Years		
Gender		
Male	54(75.0)	
Female	18(25.0)	
Insurance status		
Insured	55(76.4)	
Not Insured	17(23.6)	
Total	72(100.0)	

- 138
- 139
- 140

Received	Not received
N (%)	N (%)
31(43.1)	41(56.9)
42(58.3)	30(41.7)
43(59.7)	29(40.3)
8(11.1)	64(88.9)
28(38.9)	44(61.1)
	Received N (%) 31(43.1) 42(58.3) 43(59.7) 8(11.1) 28(38.9)

141 Table 2. Type of treatment that the study participants were receiving

142

143 The commonest primary cancers causing metastatic bone disease

144 Prostate cancer was found to be the leading cause of metastatic bone disease accounting

145 for 65.3% followed by breast cancer 18.1%, Lung cancer 4.2%, Colorectal Cancer 4.2%. This

- 146 information is summarized in table 3 below.
- 147

148 Table 3. The Common primary cancers causing metastatic bone disease

Primary		N (%)	
	Breast Cancer	13(18.1)	
	Bronchus and lung cancer	3(4.2)	
	Colorectal cancer	3(4.2)	
	Gastric adenocarcinoma	1(1.4)	
	Liver cancer	1(1.4)	
	Ovary cancer	1(1.4)	
	Prostate adenocarcinoma	47(65.3)	
	Thyroid adenocarcinoma	2(2.8)	
	Unknown	1(1.4)	
Total		72(100.0)	

151 Pattern of bone metastasis among patients with metastatic bone disease

Most of the study participants (91.7%) had multiple metastatic bone lesions involving more than one site. The spine was involved in 67(93.1%) participants followed by the pelvis 38 (52.8%) and long bones 19 (26.4%). Other bones involved were the rib cage, scapula, clavicles, sternum, mandibles and skull which together accounted for 38.9%. This information is shown in Table 4 below

157 Table 4. Location of bone metastasis

Location of bone metastasis	N (%)
Spine	67(93.1)
Pelvis	38(52.8)
Femur	15(20.8)
Humerus	3(4.2)
Other***	29(40.3)
***Other include ribcage, Thoracic, Scapula, Sku	Ill, Tibia, Clavicle and Mandible sterunum

158 159

160

161

162

163 4.2.1 Radiological pattern

We found that majority 59.7% of the study participants had osteoblastic/sclerotic while 23.6% had osteolytic and 12 (16.7%) had mixed sclerotic and lytic lesions. This information is summarized in table 5

167 Table 5. Distribution of study participants based on radiological pattern of the metastatis

168 **bone lesions**

Radiological pattern	Frequency	Percent
Osteoblastic	43	59.7
Osteolytic	17	23.6
Mixed pattern	12	16.7
Total	72	100.0

170 4.3 Skeletal related Events and Need for surgery

171 41.7% of the study participants had functional pain requiring opioid analgesics (Fig. 1) and 31% 172 had pathological fractures. 50% of the pathological fractures occurred in patients with osteolytic 173 lesions (p - value < 0.001) while only 27.3% occurred in patients with osteoblastic lesions. The rest of the fractures occurred in patients with mixed type of lesions. Table 6 shows the distribution 174 175 of the pathological fractures by Age, Gender, type of primary cancer, radiological pattern, number of lesions and site of metastasis. 176 177 178 179 Fig 1. proportions of participants based on their pain severity 180

182 Table 6. Pathological fractures according to age, sex, type of primary cancer and pattern

183 of bone metastases (fisher's exact test)

184

Independent variable	pathological fractures		Total	
-	Yes	No		P-value
Age				
<=59	8(36.4)	5(10.0)	13(18.1)	
60-74	9(40.9)	25(50.0)	34(47.2)	0.032
75+	5(22.7)	20(40.0)	25(34.7)	
Gender				
Male	12(54.5)	42(84.0)	54(75.0)	
Female	10(45.5)	8(16.0)	18(25.0)	0.016
Primary cancer				
Prostate Cancer	9(40.9)	38(76.0)	47(65.3)	
Breast Cancer	7(31.8)	6(12.0)	13(18.1)	0.015
Others	6(27.3)	6(12.0)	12(16.7)	
Radiological pattern				
Osteoblastic	6(27.3)	37(74.0)	43(59.7)	
Osteolytic	11(50.0)	6(12.0)	17(23.6)	< 0.0001
Mixed pattern	5(22.7)	7(14.0)	12(16.7)	
Number of lesion				
Single/Solitary	0(0.0)	6(12.0)	6(8.3)	
Multiple	22(100.0)	44(88.0)	66(91.7)	0.168
Site				
Spine	16(72.7)	51(79.7)	67(77.9)	
Long bones	06(27.3)	13(10.3)	19(22.1)	0.163

185

Among 67 patients with metastases to the spine, 23.9% had pathological fractures, 6% patients had spinal cord compression, 13.4% had spine instability while 70.1% had potential instability (Table 7).

190 Table 7. Spine instability based on SINS score

Interpretation	Frequency	Percentage
Stable	11	16.4
Potentially unstable	47	70.2
Unstable	9	13.4
Total	67	100.0

¹⁹¹

We found 17 patients with long bone metastases and a total of 19 long bones were involved. Among the 19 long bones, 06 (31.6%) had pathological fractures and 07 (36.8%) had impending fracture requiring prophylactic fixation. A total of 26 (36.1%) study participants had absolute indications for surgical intervention due to metastatic bone disease. These Indications with the corresponding number of study participants is shown in table 8.

197

198 Table 8. Proportion of study participants with absolute indications for surgical

199 intervention of MBD

Indication	n(%)	
Pathological fracture of long bones	06(8.3)	
Impending fracture of long bones	07(9.7)	
Unstable spine	09(12.5)	
Spinal cord compression	04(5.6)	
Total	26(36.1%)	

201 **Discussion**

202 Discussion of key findings

203 Characteristics of the study participants

In our study we found that most of patients with metastatic bone disease were elderly with a mean age of 69 +/- 11 years. These findings are similar to a study done in Nigeria among patients with metastatic prostate cancer where mean age was 67+/-1.8 years. (16) They are consistent with other studies which also showed that increasing age is associated with more skeletal metastasis. (5,7)

209 Men accounted for 75% of the study participants which is reflected by the large proportion 210 of patients in this study having prostate cancer as the primary cancer leading to bone metastases.

76.4% of the study participants had some form of health insurance which is a good observationconsidering the cost of treatment in patients with metastatic bone disease.

213

More than half of the study participants were on either chemotherapy and/or hormonal therapy with bisphosphonates. Few had received radiotherapy at a peripheral center because it is currently not offered at KCMC Hospital and most of the patients who need RT are usually reffered to a center where it is offered. Efforts are being made to start providing Radiotherapy services at KCMC and RT bankers are under construction as we write this report.

The management of patients with bone metastases needs a multidisciplinary team approach. The main goal is for symptom palliation and prevention of skeletal related events thus improve survival and the quality of life among these patients. Conventional cytotoxic chemotherapy has little effect on bone as compared to bone targeting therapies which have direct effect on bone remodeling. The use of bone targeting therapies has paved way to achieving this goal and are divided into local regional and systemic therapies. (8,10)

Local regional therapies include orthopedic surgery and radiotherapy which are aimed at pain relief and management of skeletal related events such as pathological fractures and spinal

cord compression. Systemic bone targeting therapies include the use of Bone resorption inhibitors
 (BRI's). Bisphosphonates is one example of the commonly used inhibitors of bone resorption.

229 Bisphosphonates have also been shown to stimulate innate anti-cancer immune response by up 230 regulating $\gamma\delta T$ - cells. (8)

Denosumab is another bone resorption inhibitor which is a monoclonal antibody against RANK-L. It reduses osteoclast activity by impairing the activation of osteoclasts. It also causes bone remodeling and increase survival of patients with bone metastases. Donosumab has been shown to be superior to zolendronic acid in reducing the likelihood of pathological fractures and other SRE's but there was no significant difference in overall survival improvement between denosumab and zolendronic acid. (9,17,18)

Denosumab was also shown to have less adverse events than bisphosphonates. The side
effects of bisphosphonates include osteonecrosis of the Jaw, gastro-intestinal upset and gastritis,
hypo-calcemia, fevers and skin rash.

240

Other systemic bone targeting therapies under study include the use of Tyrosine KinaseInhibitors and Immune Checkpoint Inhibitors but these are out of scope of this study.(8)

243

244 Common primary Cancers causing Metastatic Bone Disease

Prostate cancer was found to be the leading cause of metastatic bone disease followed by breast
cancer, Lung cancer, Colorectal Cancer. In our setting more than half of patients with prostate and
Breast cancer have been shown to present with bone metastasis metastasis. (7)(5) These cancers
have also been shown to be the commonest primary cancers in studies done in other parts of the
world. (1,2,9,19,20)

250 This is because the establishment of bone metastasis involve an intricate relationship between the

primary tumor and the bone micro-environment. It involves phases from the detachment of tumorcells from the primaries to the colonization of the metastatic site.

253 The vertebral venous plexus is a system of valve less veins that drains the chest cavity and pelvis.

254 It was postulated by Batson in 1940 that this system of veins is responsible for the spreading of

cancer cells to the bones. However, this does not explain the preferential homing of cancer cellsin bones. (8,21)

257

258 Paget hypothesized what is called the "Seed and soil model" where the tumor cells are the seeds 259 that will flourish and grow in a micro-environment of the organ that will provide a suitable soil.

260 The bone provides a favorable microenvironment for tumor growth due to the presence of calcium,

261 hypoxia, acidosis and various growth factors that are released from the mineralized bone matrix.

- 262 (8,21)
- 263

The homage of tumor cells into the bones is influenced by various integrins and chemokines such as CCXR4 that help the tumor cells attach to the bone marrow endothelium.

266 Metastatic bone tumors thrive in the bone micro-environment by a feed forward vicious cycle.

267 This cycle involves an interplay between the tumor cells, osteoclasts, osteoblasts, cytokines and268 growth factors.

269

270 Pattern of Bone metastases

In most of the study participants, more than one site was involved and almost all had multiple metastatic lesions (Fig. 2). This pattern was seen to be common in studies done in other parts of the world (16,20,22)

274

Fig 2. Multiple lesions of the spine; Sagittal CT images of the thoraco-lumbar spine of a lady
who had breast cancer showing multiple metastatic lesions on the spine with pathological fracture
of vertebral body

The spine was involved in 93.1% participants followed by the pelvis 52.8% and long bones 26.4%. Other bones involved were the rib cage, scapula, clavicles, sternum, mandibles and skull which together accounted for 38.9%. These findings are similar to other studies where the spine was shown to be the preferred metastatic site. (16,22,23)

These findings are explained by the hematogenous spread of the cancer cells through the Batson Venous plexus, thus increasing their propensity to lodge in the vertebral bodies.

Radiologically, 59.7% of the metastatic bone lesions were osteoblastic/sclerotic (fig. 3) while 23.6% were osteolytic and 16.7% had mixed sclerotic and lytic lesions. These findings are contrary to most of the studies we reviewed where osteolytic lesions were more common than osteoblastic lesions.(20,24,25) This might be explained by the fact that in their studies the commonest primary cancers are breast and lung malignancy while in our study the commonest primary is prostate carcinoma. Breast and lung cancer have been shown to form more lytic bone lesions than osteoblastic while prostate carcinoma forms more osteoblastic bone lesions.

- 291
- 292 Fig 3. Osteoblastic lesions; X ray image showing diffuse osteoblastic lesions involving the pelvis
- and proximal femur in a patient with prostate carcinoma attending at our center
- 294
- 295

296 Skeletal related events and Need for surgery

About a third of the study participants had pathological fractures either on spine vertebrae or the long bones. Among the patients with metastases to the spine majority (70.1%) had potential instability, 23.9% had pathological fractures, 6% had spinal cord compression and 13.4% had spine instability. This rates are lower compared to studies done in other parts of the world where more than half of their study participants had pathological fractures and neurological deficits.(9,11) This might be explained by the larger proportion of our study participants having prostate carcinoma while in their studies the leading primary cancers were Breast and lung cancer.

304 Irrespective of the site involved, 41.7% of the study participants had severe pain requiring 305 opioid analgesics. This finding differed with studies we reviewed where the value was higher in 306 one study and very low in another. (11,24)

The onset of SRE's has been shown to vary depending on the primary tumor, metastatic site and the radiological pattern. Tumors that form osteolytic metastatic lesions tend to cause more SREs such as pain and pathological fractures than those that form sclerotic lesions.(D'Oronzo*et al.*, 2019; Turpin and Duterque-coquillaud, 2020). In our study, half of the pathological fractures occurred in patients with osteolytic lesions and another 22.7% in mixed lytic and blastic lesions. This emphasizes on the risk of pathological fractures in patients with osteolytic lesions (fig 4).

314

315

Fig 4. Osteolytic lesions; X ray images in a lady who had impending fracture of the femur (A)
which was fixed by intramedullary nailing and then later presented with metastatic osteolytic
lesion involving the shaft of the Tibia (B & C).

319

Hoban et al did a Retrospective cohort study to assess the fracture risk in patients with bone
metastasis of the upper limb and found the overall fracture rate to be 76% after a mean follow up
of 3.6 years. They also found out that a Mirels' score of 7 or above had a high predictive value
for fracture risk with higher sensitivity and specificity than that recommended in lower limb
lesions. (26)

325

326 36.1% of the study participants had absolute indications for surgery. More than half of the 327 patients with long bone metastases had either a pathological fracture or had an impending fracture 328 requiring prophylactic fixation. This does not mean all these patients are fit for surgery and will 329 end up being operated. Other important surgical considerations include assessment of the general 330 medical condition of the patient such as the performance status, presence of other metastatic sites, expected survival and magnitude of the surgery to be performed. All these affect the decision on 331 332 whether to operate or not to operate. The choice of surgery whether to do internal fixation or endo-333 prosthetic reconstruction should be chosen on the basis of the location of the lesion, the extent of 334 bone destruction and the stability of the construct to outlast the life expectancy of the patient. 335 (11, 19, 27)

336

In a Multi-Center Prospective study done in France that involved 245 patients to compare those treated by surgery for fracture fixation versus those who had surgery for prophylactic fixation, they found out that more than half of the patients were operated for fracture fixation. In this study they also found out that advanced age, VAS pain score > 6, WHO grade performance and upper limb location were independent predictors for surgical fixation.(25)

In the systematic review done by Errani to assess the treatment of long bone metastasis, patients with metastasis to the LL were operated more than those with metastasis to the upper

limbs. In their study, patients were operated if expected survival was more than 6 weeks. (19)

345

346

Considering these factors, the need for surgery in patients with Metastatic bone disease further narrows down to few patients with longer anticipated survival post-surgery and those who are in good general medical condition.

This means that a huge proportion of the study participants will end up on other forms of treatment for MBD like Radiotherapy and bisphosphonates for pain relief, prevention of SRE's and progression of the disease.

353 Study Limitations and Strengths

354 Study limitations

Currently we do not have PET – CT scan and Radiotherapy services at our center. It is very likely that some lesions were missed and this was an important imaging modality for appropriate description of the pattern of the skeletal metastases. Also the lack RT services leads poor continuity of care as there is a significant number of patients who are reffered to other centers for Radiotherapy. This posed a challenge in acquiring information because it is not easy to access investigation results and data from a different center.

361 This is a single center observational study, so results can only be generalized with caution.

362

363 Strength

This study is first of its kind in our setting, we hope it will pave way for further studies on MBD

366 Conclusion and recommendations

367 As stated prostate cancer is the leading cause of metastatic bone disease followed by breast 368 cancer. So the role of targeted hormonal therapies cannot be over-emphasized. Also routine

screening for breast cancer in females will help early detection and treatment to prevent advanceddisease.

371

Most MBD present with multiple lesions involving multiple sites but the spine was the mostly affected site with a third of the patients presenting with pathological fractures. Despite this, a lesser number of the patients will be fit for surgery and so Radiotherapy and other non-surgical treatments will be preferred. A multicenter prospective study which will also look on survival and life expectancy will give more powerful findings that may guide in creating local protocols and guidelines for optimal treatment of these patients in our setting.

- 379

380 Acknowledgements

381	I would like to thank the management of Kilimanjaro Christian Medical Centre for
382	allowing me to conduct this study. I also extend my sincere gratitude to everyone in the
383	Department of Orthopedics and Trauma at KCMC for their valuable contributions.
384	Special thanks to the staff at the Cancer Care center at KCMC with special note to
385	Yotham Gwanika for his assistance during analysis and data processing from the cancer registry.
386	

387 **References**

- Ryan C, Stoltzfus KC, Horn S, Chen H, Louie A V., Lehrer EJ, et al. Epidemiology of bone metastases. Bone [Internet]. 2022;158:115783. Available from: https://doi.org/10.1016/j.bone.2020.115783
- Jiang W, Rixiati Y, Zhao B, Li Y, Tang C, Liu J. Incidence, prevalence, and outcomes of systemic malignancy with bone metastases. J Orthop Surg. 2020;28(2):1–5.
- Mduma S. CLINICO-MORPHOLOGICAL PATTERN OF MUSKULOSKELETAL
 TUMORS AMONG PATIENTS SEEN AT MUHIMBILI ORTHOPEDIC INSTITUTE.
 2016.
- Mabula JB, Mchembe MD, Chalya PL, Giiti G, Chandika AB, Rambau P, et al. Stage at diagnosis, clinicopathological and treatment patterns of breast cancer at Bugando medical centre in north-western Tanzania. Tanzan J Health Res. 2012;14(4):1–14.
- Ekpe E, Shaikh AJ, Shah J, Jacobson JS, Sayed S. Metastatic breast cancer in Kenya:
 Presentation, pathologic characteristics, and patterns—findings from a tertiary cancer
 center. J Glob Oncol. 2019;2019(5):14–6.
- Gnanamuttupulle M, Henke O, Ntundu SH, Serventi F, Mwakipunda LE, Amsi P, et al.
 Clinicopathological characteristics of breast cancer patients from Northern Tanzania:
 common aspects of late stage presentation and triple negative breast cancer. Available
 from: https://doi.org/10.3332/ecancer.2021.1282
- Kibona S, Mbwambo O, Ngowi N, Bright F, Mbwambo J, Mteta A, et al. Correlation
 Between Bone Metastases and PSA Among Prostate Cancer Patients at Kilimanjaro
 Christian Medical Centre from June 2018 to May 2019. Int J Clin Urol. 2021;5(1):47.
- B. D'Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management. J Bone Oncol [Internet].
 2019;15(August 2018):100205. Available from: https://doi.org/10.1016/j.jbo.2018.10.004
- 411 2019,19 (August 2018).100205. Available from: https://doi.org/10.1016/j.jb0.2018.10
 412 9. Turpin A, Duterque-coquillaud M. Bone Metastasis : Current State of Play.
 413 2020;13(2):308–20.
- 414 10. Bickels J, Dadia S, Lidar Z. Surgical management of metastatic bone disease. J Bone Jt
 415 Surg Ser A. 2009;91(6):1503–16.
- 416 11. Bouthors C, Prost S, Court C, Blondel B, Charles YP, Fuentes S, et al. Outcomes of surgical treatments of spinal metastases : a prospective study. 2019;
- 418 12. Sørensen MS, Horstmann PF, Hindsø K, Petersen MM. Use of endoprostheses for
 419 proximal femur metastases results in a rapid rehabilitation and low risk of implant failure
 420 A prospective population-based study. J Bone Oncol [Internet]. 2019;19(July):100264.
- 421 Available from: https://doi.org/10.1016/j.jbo.2019.100264
- 422 13. Sahgal A, Schouten R, Versteeg A, Boriani S, Pal Varga P, Rhines L, et al. A Multi423 institutional Study Evaluating the Reliability of the Spinal Instability Neoplastic Score
 424 (SINS) Among Radiation Oncologists for Spinal Metastases. Int J Radiat Oncol.
 425 2014;90(1):S350.
- 426 14. Jawad MU, Scully SP. In brief: Classifications in brief: Mirels' classification: Metastatic
 427 disease in long bones and impending pathologic fracture. Clin Orthop Relat Res.
 428 2010;468(10):2825–7.
- Anract P, Biau D, Boudou-Rouquette P. Metastatic fractures of long limb bones. Orthop
 Traumatol Surg Res [Internet]. 2017;103(1):S41–51. Available from:
 http://dx.doi.org/10.1016/j.otsr.2016.11.001

- 432 16. Folasire A, Ntekim A, Omikunle A, Ali-Gombe M. Association of gleason risk groups
 433 with metastatic sites in prostate cancer. African J Biomed Res. 2015;18(3):189–96.
- 434 17. Zheng GZ, Chang B, Lin FX, Xie D, Hu QX, Yu GY, et al. Meta-analysis comparing
 435 denosumab and zoledronic acid for treatment of bone metastases in patients with advanced
 436 solid tumours. Eur J Cancer Care (Engl). 2017;26(6):1–7.
- Al Farii H, Frazer A, Farahdel L, AlFayyadh F, Turcotte R. Bisphosphonates Versus
 Denosumab for Prevention of Pathological Fracture in Advanced Cancers With Bone
 Metastasis: A Meta-analysis of Randomized Controlled Trials. J Am Acad Orthop Surg
 Glob Res Rev. 2020;4(8):E2000045.
- 441 19. Errani C, Mavrogenis AF, Cevolani L, Spinelli S, Piccioli A, Maccauro G, et al.
 442 Treatment for long bone metastases based on a systematic literature review. Eur J Orthop
 443 Surg Traumatol. 2017;27(2):205–11.
- Flaifel A, Tabaja F, Bannoura S, Loya A, Mushtaq S, Khalifeh I. Patterns of
 pathologically confirmed metastasis to bone in Near East population. Cancer Epidemiol
 [Internet]. 2018;54(March):7–11. Available from:
- 447 https://doi.org/10.1016/j.canep.2018.03.002
- Chiechi A, Guise T. Pathobiology of Osteolytic and Osteoblastic Bone Metastases. In:
 Randall RL, editor. Salt Lake City, UT, USA: Springer Science+Business Media New
 York; 2016. p. 15.
- 22. Zhu M, Liu X, Qu Y, Hu S, Zhang Y, Li W, et al. Bone metastasis pattern of cancer
 patients with bone metastasis but no visceral metastasis. J Bone Oncol.
 2019;15(November 2018):1–5.
- Adewuyi SA, Chom ND, Humera M, Samaila MOA. Pattern of skeletal metastases from
 breast cancer in an Asian population. Niger J Surg Res. 2006;8(3–4):128–31.
- 456 24. Ramsey DC, Lam PW, Hayden J, Doung YC, Gundle KR. Mirels Scores in Patients
 457 Undergoing Prophylactic Stabilization for Femoral Metastatic Bone Disease in the
 458 Veterans Administration Healthcare System. J Am Acad Orthop Surg Glob Res Rev.
 459 2020;4(9).
- 460 25. Crenn V, Carlier C, Gouin F, Sailhan F, Bonnevialle P. High rate of fracture in long-bone metastasis: Proposal for an improved Mirels predictive score. Orthop Traumatol Surg Res. 2020;106(6):1005–11.
- 463 26. Hoban KA, Downie S, Adamson DJA, MacLean JG, Cool P, Jariwala AC. Mirels' score
 464 for upper limb metastatic lesions: do we need a different cutoff for recommending
 465 prophylactic fixation? JSES Int [Internet]. 2022;3–9. Available from:
- 466 https://doi.org/10.1016/j.jseint.2022.03.006
- 467 27. Choi D, Crockard A, Bunger C, Harms J, Kawahara N, Mazel C, et al. Review of
 468 metastatic spine tumour classification and indications for surgery: The consensus
 469 statement of the Global Spine Tumour Study Group. Eur Spine J. 2010;19(2):215–22.
- 470 471
- 472
- 473
- 474

475 Supporting information

- 476 S1 File. Informed consent
- 477 S2 file. ASIA reference manual
- 478
- 479 S3 file. STROBE statement











